HLSE:ORNBVPharmaceuticals
Orion Oyj (HLSE:ORNBV) Nivolumab Deal Puts Its Valuation Story Back In Focus
Why Orion Oyj’s New Nivolumab Biosimilar Deal Matters
Orion Oyj (HLSE:ORNBV) has signed an agreement with Shilpa Biologicals to commercialise an intravenous nivolumab biosimilar in Europe, giving Orion exclusive rights to distribute, market, and sell the therapy.
Shilpa Biologicals will supply the nivolumab biosimilar to Orion and receive development and regulatory milestone payments. This creates a structure where both parties share economic interest in the product’s progress and European...